(70 days)
The Apnea Risk Evaluation System (ARES™), Model 610 is indicated for use in the diagnostic evaluation by a physician of adult patients with possible sleep apnea. The ARES™ can record and score respiratory events during sleep (e.g., apneas, hypopneas, mixed apneas and flow limiting events). The device is designed for prescription use in home diagnosis of adults with possible sleep-related breathing disorders.
The Apnea Risk Evaluation System (ARES™) includes a device called a Unicorder which records oxygen saturation, pulse rate, snoring level, head movement and head position, and airflow. Additionally, a physiological signal from the forehead used to stage sleep or respiratory effort signal obtained from an optional piezo respiratory effort belt can be acquired. The battery powered Unicorder provides sufficient capacity to record two nights of data. The device monitors signal quality during acquisition and notifies the user via voice messages when adjustments are required. A standard USB cable connects the Unicorder to a USB port on a host computer when patient data is to be uploaded or downloaded. The USB cable provides power to the Unicorder during recharging from the host computer or from a USB wall charger. The Unicorder cannot record nor can it be worn by the patient when connected to the host computer or the wall charger. Software controls the uploading and downloading of data to the Unicorder, processes the sleep study data and generates a sleep study report. The ARES™ can auto-detect positional and non-positional obstructive and mixed apneas and hypopneas similarly to polysomnography. It can detect sleep/wake and REM and non-REM. After the sleep study has been completed, data is transferred off the Unicorder is prepared for the next study. The downloaded sleep study record is then processed with the ARES™ Insight software to transform the raw signals and derive and assess changes in oxygen saturation (SpQ2), pulse rate, head movement, head position, snoring sounds, airflow, and EEG or respiratory effort. The red and IR signals are used to calculate the SpO- and pulse rate: The actigraphy signals are transformed to obtain head movement and head position. A clinician can convert an auto-detected obstructive apnea to a central apnea based on visual inspection of the waveforms. ARES™ Screener can predict pre-test probability of obstructive sleep apnea (OSA). The ARES™ can assist the physician to identify patients who will likely have a successful OSA treatment outcome, including CPAP and oral appliance therapies. ARES™ can also help identify patients who would benefit from a laboratory PAP titration.
Here's an analysis of the provided text regarding the ARES device's acceptance criteria and studies:
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Clinical Study 1: Equivalence of ARES™ chest belt signals to predicate device (Compumedics Somté) in response to breathing events. | The ARES™ chest signal and Somté chest signal were equivalent in their response to three types of breathing events. The acceptance criteria of at least 95% waveforms being equivalent was met. The study result is Pass. |
| Clinical Study 2: Ability for users to properly apply the ARES™ with chest belt such that signals are useful for interpretation. | At least 95% of signals from the ARES effort belt recorded during overnight studies are interpretable and behave consistently based on the airflow signal. Based on subject feedback from a Usability survey, the Unicorder with effort belt can be easily used by patients. |
| Non-Clinical Testing: Compliance with system-level requirements. | All features of the ARES™ Model 610 were compliant with the system level requirements. |
| Non-Clinical Testing: Correct acquisition and storage of signals from a cleared respiratory effort belt. | The ARES Unicorder correctly acquires and stores the signal from a cleared respiratory effort belt. |
| Non-Clinical Testing: Signals acquired provide similar information for physician interpretation compared to the predicate device. | Signals acquired with the ARES™ Model 610 provide similar information as compared to the predicate device that would allow a physician, trained in sleep medicine to interpret the signals. Snapshots acquired from the new and predicate device provide similar information that would allow a physician, trained in sleep medicine, to interpret the signals. |
| Non-Clinical Testing: Conformity to electrical safety and electromagnetic compatibility standards. | Conformity to FDA recognized consensus standards and voluntary standards, including IEC 60601-1-1:1988+A1:1991+A2:1995 (Medical Electrical Equipment - Part 1: General requirements for safety) and IEC 60601-1-2: 2007 (Electromagnetic compatibility - requirements and tests), was demonstrated. (No specific performance values for these are given, but compliance implies meeting the criteria within the standards). |
2. Sample Size Used for the Test Set and Data Provenance:
The document mentions "Two clinical studies were conducted," but does not explicitly state the sample size for either clinical study.
The data provenance is not explicitly stated (e.g., country of origin, retrospective or prospective). However, the description of clinical studies implies prospective data collection for the purpose of validating the device.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:
The document does not specify the number of experts used to establish ground truth for the clinical studies.
It notes that the "signals acquired... would allow a physician, trained in sleep medicine to interpret the signals." This implies that the interpretation of signals for the "ground truth" or comparison in the equivalence study would be done by physicians trained in sleep medicine, but their specific qualifications (e.g., years of experience) are not provided.
4. Adjudication Method for the Test Set:
The document does not describe any specific adjudication method (e.g., 2+1, 3+1). For the first clinical study, it states the ARES chest signal and Somté chest signal were "equivalent in their response," implying a direct comparison rather than a consensus among multiple human readers.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size:
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done as described in this 510(k) summary. The clinical studies focused on signal equivalence and interpretability, not on the improvement of human readers with or without AI assistance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done:
The document mentions that the ARES™ can "auto-detect positional and non-positional obstructive and mixed apneas and hypopneas similarly to polysomnography" and that "A clinician can convert an auto-detected obstructive apnea to a central apnea based on visual inspection of the waveforms."
However, beyond these functional descriptions, the reported clinical studies primarily focus on signal acquisition, equivalence, and interpretability by a physician, rather than a standalone performance evaluation of the scoring algorithm's accuracy against a gold standard without human intervention. The statement "at least 95% of signals from the ARES effort belt recorded during overnight studies are interpretable and behave consistently based on the airflow signal" suggests a focus on the quality of the raw data for human interpretation, not the autonomous performance of an algorithm.
7. The Type of Ground Truth Used:
For the first clinical study (signal equivalence), the "ground truth" appears to be the signals simultaneously acquired using the predicate device, Compumedics Somté System. This functions as a form of comparative ground truth against an established device.
For the second clinical study (usability/interpretability), the ground truth for "interpretable and behave consistently" is implied to be expert visual assessment based on consistency with airflow signals by a physician trained in sleep medicine. Additionally, subject feedback from a Usability survey served as a form of ground truth for ease of use.
8. The Sample Size for the Training Set:
The document does not provide any information regarding a training set or its sample size. This 510(k) summary focuses on the validation of modifications to an existing device (adding a respiratory effort belt) and demonstrating substantial equivalence, rather than the initial development and training of the core algorithmic components for apnea detection.
9. How the Ground Truth for the Training Set Was Established:
Since no training set information is provided, the method for establishing its ground truth is also not described.
{0}------------------------------------------------
JUL - 7 2011
111194
510(K) SUMMARY
In accordance with 21 CFR 807.92 the following summary of information is provided:
้ โ
April 25, 2011
SUBMITTER:
Advanced Brain Monitoring 2237 Faraday Avenue, Suite 100 Carlsbad, CA 92008 T 760.720.0099 F 760.720.3337
PRIMARY CONTACT PERSON:
Adrienne Lenz, RAC Founder Pathway Regulatory Consulting, LLC T 262-290-0023
SECONDARY CONTACT PERSON:
Dan Levendowski President and Co-founder Advanced Brain Monitoring, Inc.
DEVICE:
TRADE NAME: Apnea Risk Evaluation System (ARESTM), Model 610
COMMON/USUAL NAME: ARES
CLASSIFICATION NAMES: 868.2375 Breathing frequency monitor
PRODUCT CODE: MNR
PREDICATE DEVICE(S):
K110705 Apnea Risk Evaluation System (ARES), Model 610
K090484 Respironics Alice PDX
K072201 Compumedics Somté
{1}------------------------------------------------
DEVICE DESCRIPTION:
The Apnea Risk Evaluation System (ARES™) includes a device called a Unicorder which records oxygen saturation, pulse rate, snoring level, head movement and head position, and airflow. Additionally, a physiological signal from the forehead used to stage sleep or respiratory effort signal obtained from an optional piezo respiratory effort belt can be acquired. The battery powered Unicorder provides sufficient capacity to record two nights of data. The device monitors signal quality during acquisition and notifies the user via voice messages when adjustments are required.
A standard USB cable connects the Unicorder to a USB port on a host computer when patient data is to be uploaded or downloaded. The USB cable provides power to the Unicorder during recharging from the host computer or from a USB wall charger. The Unicorder cannot record nor can it be worn by the patient when connected to the host computer or the wall charger.
Software controls the uploading and downloading of data to the Unicorder, processes the sleep study data and generates a sleep study report. The ARES™ can auto-detect positional and non-positional obstructive and mixed apneas and hypopneas similarly to polysomnography. It can detect sleep/wake and REM and non-REM.
After the sleep study has been completed, data is transferred off the Unicorder is prepared for the next study. The downloaded sleep study record is then processed with the ARES™ Insight software to transform the raw signals and derive and assess changes in oxygen saturation (SpQ2), pulse rate, head movement, head position, snoring sounds, airflow, and EEG or respiratory effort. The red and IR signals are used to calculate the SpO- and pulse rate: The actigraphy signals are transformed to obtain head movement and head position. A clinician can convert an auto-detected obstructive apnea to a central apnea based on visual inspection of the waveforms.
ARES™ Screener can predict pre-test probability of obstructive sleep apnea (OSA). The ARES™ can assist the physician to identify patients who will likely have a successful OSA treatment outcome, including CPAP and oral appliance therapies. ARES™ can also help identify patients who would benefit from a laboratory PAP titration.
INTENDED USE:
The Apnea Risk Evaluation System (ARES™), Model 610 is indicated for use in the diagnostic evaluation by a physician of adult patients with possible sleep apnea. The ARES™ can record and score respiratory events during sleep (e.g., apneas, hypopneas, mixed apneas and flow limiting events). The device is designed for prescription use in home diagnosis of adults with possible sleep-related breathing disorders.
{2}------------------------------------------------
TECHNOLOGY:
The Apnea Risk Evaluation System (ARES™), Model 610 with the chest belt has the same indications for use and uses the same fundamental technology as the ARES™ Model 610 cleared via K110705. The ARES™ Model 610 with Respiratory Effort Belt is identical to the predicate ARES™ Model 610 without chest belt with the following modifications:
-
- Modification of the flex circuit to allow amplifier input from either two EEG sensors (previously cleared, K071230) or two connectors for input from a commercially available piezo respiratory effort belt.
-
- Updated firmware and software to allow acquisition and presentation of either the EEG signal or the effort belt signal.
DETERMINATION OF SUBSTANTIAL EQUIVALENCE:
COMPARISON TO PREDICATE DEVICES
The ARES™ Model 610 with respiratory effort belt has the same intended use as the cleared ARES™ Model 610. All features are identical except those described in the table below.
| Characteristic | ARES™ Model 610(K110705) | ARES™ Model 610 (New) | Equivalence Discussion |
|---|---|---|---|
| Data acquisition | Via forehead sensor:• Red/IR LEDs• Photodetector• Microphone• Nasal Cannula• Nasal pressuretransducer• 3D accelerometers• EEG sensor | Via forehead sensor:• Red/IR LEDs• Photodetector• Microphone• Nasal Cannula• Nasal pressuretransducer• 3D accelerometers• EEG sensor (optional– not available whenEffort Belt is used)• Respiratory EffortBelt (optional - notavailable when EEG isused) | The ARES has beenmodified to acquire datafrom cleared piezorespiratory effort belts,similarly to RespironicsAlice PDX (K090484) andCompumedics Somté(K072201). |
| Respiratory Effort | Not available | 256 samples/sechardware acquisition,displayed at 25samples/sec |
{3}------------------------------------------------
SUMMARY OF NON-CLINICAL TESTS:
Support for the substantial equivalence of the ARES™ Model 610 was provided as a result of risk management and testing which included electrical safety, performance and software tests. This testing includes conformity to FDA recognized consensus standards and voluntary standards as follows:
| StandardNumber | Standard Title |
|---|---|
| IEC 60601-1-1:1988+A1:1991+A2: 1995 | Medical Electrical Equipment - Part 1: General requirements for safety |
| IEC 60601-1-2: 2007 | Medical Electrical Equipment Part 1-2: Collateral standard: Electromagneticcompatibility - requirements and tests |
Additional verification and validation testing confirmed:
- All features of the ARES'" Model 610 were compliant with the system level requirements. .
- . The ARES Unicorder correctly acquires and stores the signal from a cleared respiratory effort belt.
- Signals acquired with the ARES™ Model 610 provide similar information as compared to the . predicate device that would allow a physician, trained in sleep medicine to interpret the signals.
SUMMARY OF CLINICAL TESTS:
Two clinical studies were conducted to validate the ARES™ with chest belt. One study compared signals acquired from subjects with the ARES™ chest belt to those simultaneously acquired using the Compumedics Somté System (K021176) and confirmed the ARES™ chest signal and Somté chest signal were equivalent in their response to three types of breathing events. Snapshots acquired from the new and predicate device provide similar information that would allow a physician, trained in sleep medicine, to interpret the signals. The acceptance criteria of at least 95% waveforms being equivalent was met and the study result is Pass.
The second study evaluated the ability for users of the ARES™ with chest belt to properly apply the device such that signals acquired were useful for interpretation. The results support that at least 95% of signals from the ARES effort belt recorded during overnight studies are interpretable and behave consistently based on the airflow signal. Based on subject feedback from a Usability survey, the Unicorder with effort belt can be easily used by patients.
CONCLUSION:
The conclusions drawn from the nonclinical and clinical tests demonstrate equivalent performance of the Apnea Risk Evaluation System (ARES™), Model 610 and the legally marketed devices. The Apnea Risk Evaluation System (ARESTM), Model 610 is substantially equivalent to the predicate devices.
{4}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an emblem of an eagle with its wings spread.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Advanced Brain Monitoring, Incorporated C/O Ms. Adrienne Lenz, RAC Pathway Regulatory Consulting, LLC 2511 Fox River Circle Waukesha. Wisconsin 53189
JUL - 7 2011
Re: K11194
Trade/Device Name: Apnea Risk Evaluation Systems (ARES) Regulation Number: 21 CFR 868.2375 Regulation Name: Breathing Frequency Monitor Regulatory Class: II Product Code: MNR Dated: June 9, 2011 Received: June 10, 2011
Dear Ms. Lenz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{5}------------------------------------------------
Page 2 - Ms. Lenz
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that.FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/ CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Anthony 29. Watson
Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
510(k) Number (if known):
Device Name: Apnea Risk Evaluation System (ARES)
Indications for Use:
The Apnea Risk Evaluation System (ARES™), Model 610 is indicated for use in the diagnostic evaluation by a physician of adult patients with possible sleep apnea. The ARES™ can record and score respiratory events during sleep (e.g., apneas, hypopneas, mixed apneas and flow limiting events). The device is designed for prescription use in home diagnosis of adults with possible sleep-related breathing disorders.
Prescription Use_ X AND/OR
Ove
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Dan Cutler
(Division Sign Off)
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
510(k) Number: K111994
§ 868.2375 Breathing frequency monitor.
(a)
Identification. A breathing (ventilatory) frequency monitor is a device intended to measure or monitor a patient's respiratory rate. The device may provide an audible or visible alarm when the respiratory rate, averaged over time, is outside operator settable alarm limits. This device does not include the apnea monitor classified in § 868.2377.(b)
Classification. Class II (performance standards).